Sameer Melinkeri <br/><br/>
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study 

 -  Lancet Haematol  2025 
 -  Apr;12(4):e282-e293. 
<br/><br/> DOI: 10.1016/S2352-3026(24)00377-6 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Hematology